Arnold Levine will discuss his discovery of p53 and the evolution of the field since then, and Jon Chen will discuss the use of single-cell phosphoproteomics in identifying changes in key signaling networks, including p53.

By infecting glioblastoma cells but not healthy brain tissue, some form of the virus could serve a therapeutic purpose.

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

Inhaling combustion-produced particles may lead to the development of brain tumors.

The results of an early trial in 31 brain cancer patients finds immune activity boosted in the tumor, and possibly longer survival.

Researchers use 3-D printing technology to construct a brain cancer model that accurately recapitulated in vivo biology and predicted patient drug responses.

How researchers create a glioblastoma on a chip that can predict patients’ response to treatments

The molecular processes that lead males to be more susceptible to the disease are only beginning to come to light.

The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.

Researchers plan to turn cancer cells into defectors, engineering them to kill the tumors from whence they came, and have tested the approach in mice.

More than one-fifth of individuals treated with the genetically modified virus survived at least three years.

The discovery suggests that the immune checkpoint can operate at a further distance from tumor cells than previously believed.

Neutrophils loaded with the chemotherapy drug paclitaxel traverse the blood-brain barrier and kill residual cancer cells after tumor-resection surgery in mice.

Fragments of circulating DNA from tumors are around 20 to 30 base pairs shorter than those from healthy cells, researchers report.